KaliVir Immunotherapeutics
1 known investors
KaliVir Immunotherapeutics develops oncolytic viral immunotherapies for the treatment of advanced solid tumors, including its VET3-TGI candidate being evaluated in combination with checkpoint inhibitors. The company operates in the immuno-oncology and biotechnology sector.
Founders & leadership
ST
Stephen ThorneinCo-founder & Chief Scientific Officer
SG
Schond GreenwayChief Financial Officer
JB
James BurkeChief Medical Officer
Investors · 1
Funding
SEC filings, press & company announcements$14M disclosed across 1 of 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
KaliVir raises USD 14m as oncolytic virus clears first IV cohortallsci.com · Aug 2026
KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does KaliVir Immunotherapeutics do?
- KaliVir Immunotherapeutics develops oncolytic viral immunotherapies for the treatment of advanced solid tumors, including its VET3-TGI candidate being evaluated in combination with checkpoint inhibitors. The company operates in the immuno-oncology and biotechnology sector.
- Who founded KaliVir Immunotherapeutics?
- KaliVir Immunotherapeutics was founded by Stephen Thorne.
- Who are KaliVir Immunotherapeutics's investors?
- KaliVir Immunotherapeutics's investors include Premier Partners.
- How much funding has KaliVir Immunotherapeutics raised?
- KaliVir Immunotherapeutics has disclosed $14M raised across 1 of its 2 known rounds.